✓ Medically reviewed✍️ HairBase editorial team📅 Last updated: June 14, 2026⏱ 1 min read
💡 Quick answer
Oral finasteride 1 mg is an FDA-approved, proven treatment for male androgenetic alopecia. It targets the root driver of the condition: by inhibiting type
As an AliExpress affiliate, we may earn a commission from qualifying purchases.
Evidence A · Proven
Oral finasteride 1 mg is an FDA-approved, proven treatment for male androgenetic alopecia. It targets the root driver of the condition: by inhibiting type II 5-alpha-reductase (5AR), the enzyme that converts testosterone into DHT, it lowers DHT in the scalp and bloodstream. Because it can slow or partly reverse the follicular miniaturization that causes thinning, it works on the cause itself and is often paired with minoxidil, which works by a complementary mechanism.
As with other proven treatments, the effect builds gradually over 4 to 12 months, and results are maintained only with continued use — stopping reverses the benefit. A minority of men report sexual side effects such as reduced libido or changes in erectile or ejaculatory function. "Post-finasteride syndrome," in which symptoms are said to persist after stopping, is reported but remains debated and unproven; an honest view neither asserts it as established nor dismisses it outright.
Pregnancy warning: finasteride is teratogenic and can harm a developing male fetus, so women who are or may become pregnant must not even handle crushed or broken tablets. The drug also lowers PSA, a prostate-cancer screening marker, so always tell any clinician you are taking it before PSA testing or a prostate evaluation.
Finasteride (oral) is one piece — build the whole plan
See how it ranks against every option, tuned to your stage, goal and budget.
1992FDA approves finasteride 5 mg (Proscar), a type II 5-alpha-reductase inhibitor, for benign prostatic hyperplasia — establishing the molecule (Merck, MK-906) later repurposed at lower dose for hair loss.
1997FDA approves finasteride 1 mg (Propecia) on December 19, 1997 — the first oral drug approved for male androgenetic alopecia, based on Merck's pivotal Phase III program.
1998Publication of the landmark Phase III trials (Kaufman et al., Finasteride Male Pattern Hair Loss Study Group) in JAAD, providing the primary efficacy evidence underpinning the approval.
20085-year multinational extension data published (Kaufman et al., Eur J Dermatol), demonstrating sustained long-term benefit and a 93% relative reduction vs placebo in developing further visible hair loss.
2018Network meta-analysis (Gupta et al., JEADV) ranks finasteride among effective non-surgical treatments but formally grades the finasteride-vs-placebo evidence as 'very low' quality, signaling consensus on efficacy alongside limited trial quality.
Key clinical studies
Kaufman et al. (Finasteride Male Pattern Hair Loss Study Group), 19981998
Two 1-year double-blind RCTs, 1,553 men aged 18-41 with vertex MPHL; 1,215 continued into a blinded 2nd-year extension
Finasteride 1 mg/day increased hair count vs placebo by 107 hairs at 1 year and 138 hairs at 2 years in the 1-inch target area (both p<0.001); placebo patients showed progressive loss. Established efficacy for slowing loss and promoting regrowth.
Journal of the American Academy of Dermatology (JAAD), 39(4 Pt 1):578-589
Kaufman et al. (5-year multinational data), 20082008
Long-term analysis of the Phase III cohort, 1,553 men treated with finasteride 1 mg/day or placebo for up to 5 years
Over 5 years, finasteride 1 mg produced a 93% relative decrease vs placebo in the likelihood of developing further visible hair loss (95% CI 89-97%; p<0.001), with sustained benefit; placebo patients progressively worsened.
European Journal of Dermatology (Eur J Dermatol)
Gupta et al. (network meta-analysis), 20182018
Systematic review and network meta-analysis; 78 studies identified, 22 with usable data, covering finasteride, dutasteride, minoxidil, PRP and LLLT in androgenetic alopecia
Finasteride 1 mg was an effective treatment with mean hair-count change broadly comparable to other active options, but the authors graded the finasteride-vs-placebo evidence as 'very low' quality, underscoring the need for higher-quality RCTs.
Journal of the European Academy of Dermatology and Venereology (JEADV)
Latest research: Recent work (2023-2026) has shifted toward topical finasteride and low-dose oral combinations (e.g., finasteride plus low-dose oral or topical minoxidil) aimed at preserving efficacy while reducing systemic DHT suppression and sexual side effects; however, topical finasteride remains non-FDA-approved (compounded), and in April 2025 the FDA issued a safety communication on adverse events linked to compounded topical formulations, keeping the safety profile an active research and pharmacovigilance focus.
Summaries reflect published, peer-reviewed research and are not medical advice. See the linked sources for details.
I'm worried about sexual side effects — how common are they?
Reduced libido and changes in erectile or ejaculatory function are reported in a minority of men, not the majority, and often resolve after stopping. "Post-finasteride syndrome," where symptoms persist after discontinuation, is reported but its cause-and-effect link is still debated. If side effects concern you or appear, discuss them with a clinician rather than deciding on your own.
Can women take finasteride?
Finasteride is FDA-approved only for men, and crucially, women who are or may become pregnant must not take it or even handle broken tablets because of the risk of harm to a male fetus. There are other proven options for female pattern hair loss, so see a dermatologist for an individualized plan.
Will it affect my prostate (PSA) test?
Yes — finasteride lowers PSA levels, which can affect how the result is interpreted. Always tell your doctor you are taking it before a PSA test or prostate evaluation so the result can be assessed accurately.
Not medical advice. General education only; it does not replace diagnosis or treatment by a licensed professional. Consult a board-certified dermatologist before starting, stopping or changing any treatment.